MedTrace Logo

Lidocaine for Diabetic Peripheral Neuropathy

NCT02363803 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2019-11-15

Study results available
· View outcomes & findings →

Summary

Diabetic nerve pain \[painful diabetic peripheral neuropathy\] is a common medical problem with few reliably effective treatments. There is some evidence that sensory testing may help determine how individuals will respond to analgesic therapy. In this study, the investigators are evaluating the relationship between sensory testing and subject response to lidocaine infusion therapy.

Conditions

Interventions

DRUG

lidocaine

lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.

DRUG

Placebo

Normal saline, approved for hypovolemia, and homeostasis.

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Simon Haroutounian, PhD · Department of Anesthesiology, WUSTL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-10-17
Completion
2018-10-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02363803 on ClinicalTrials.gov